Online inquiry

IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8535MR)

This product GTTS-WQ8535MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD4 gene. The antibody can be applied in AIDS research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000616.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 920
UniProt ID P01730
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8535MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10504MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY3002813
GTTS-WQ7281MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ1707MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ7618MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ264MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 17-1A
GTTS-WQ13578MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA QAX-576
GTTS-WQ12202MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MORAb-022
GTTS-WQ1168MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABP 501
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW